Shs · CUSIP G6674U108 · who reports it, how much, and how much it matters to them
16 of the 720 hedge fund managers we track reported shares of NovoCure Ltd (Nasdaq: NVCR) on Form 13F for 30 June 2026. Between them they reported USD 101m. The largest position belongs to Renaissance Technologies, at USD 30m. The manager with the most riding on it is Palo Alto Investors, where it is 2.7% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Renaissance Technologies13 funds on PPLI.com | USD 30m | 0.0% |
| 2 | Palo Alto Investors6 funds on PPLI.com | USD 19m | 2.7% |
| 3 | D. E. Shaw & Co.15 funds on PPLI.com | USD 15m | 0.0% |
| 4 | POINT72 Asset Management17 funds on PPLI.com | USD 12m | 0.0% |
| 5 | Balyasny Asset Management25 funds on PPLI.com | USD 7.3m | 0.0% |
| 6 | Millennium Management6 funds on PPLI.com | USD 4.2m | 0.0% |
| 7 | Tudor Investment Corporation10 funds on PPLI.com | USD 4.1m | 0.0% |
| 8 | Capital Fund Management S.A.12 funds on PPLI.com | USD 3.1m | 0.0% |
| 9 | Citadel Advisors32 funds on PPLI.com | USD 2.4m | 0.0% |
| 10 | Dark Forest Capital Management2 funds on PPLI.com | USD 1.2m | 0.1% |
| 11 | Engineers Gate Manager1 fund on PPLI.com | USD 1.1m | 0.0% |
| 12 | Aquatic Capital Management3 funds on PPLI.com | USD 595,000 | 0.0% |
| 13 | Two Sigma Investments35 funds on PPLI.com | USD 321,000 | 0.0% |
| 14 | Edgestream Partners5 funds on PPLI.com | USD 301,000 | 0.0% |
| 15 | Walleye Capital8 funds on PPLI.com | USD 23,255 | 0.0% |
| 16 | The Quarry1 fund on PPLI.com | USD 3,409 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Palo Alto Investors | USD 19m | 2.7% |
| 2 | Dark Forest Capital Management | USD 1.2m | 0.1% |
| 3 | Renaissance Technologies | USD 30m | 0.0% |
| 4 | Aquatic Capital Management | USD 595,000 | 0.0% |
| 5 | Capital Fund Management S.A. | USD 3.1m | 0.0% |
| 6 | Engineers Gate Manager | USD 1.1m | 0.0% |
| 7 | POINT72 Asset Management | USD 12m | 0.0% |
| 8 | Balyasny Asset Management | USD 7.3m | 0.0% |
| 9 | Edgestream Partners | USD 301,000 | 0.0% |
| 10 | D. E. Shaw & Co. | USD 15m | 0.0% |
NovoCure Ltd trades under the symbol NVCR on the Nasdaq. Its CUSIP, the code used on Form 13F, is G6674U108.
16 of the 720 hedge fund managers PPLI.com tracks reported NovoCure Ltd shares on Form 13F for 30 June 2026. The largest reported positions were held by Renaissance Technologies (USD 30m), Palo Alto Investors (USD 19m), D. E. Shaw & Co. (USD 15m), POINT72 Asset Management (USD 12m) and Balyasny Asset Management (USD 7.3m).
16 managers in our coverage reported it, and between them they run 191 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Palo Alto Investors, where the position was 2.7% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with NovoCure Ltd or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.